The assessment tool determines the concentration of all cholesterol types within the bloodstream, excluding high-density lipoprotein cholesterol. This calculation is derived by subtracting the high-density lipoprotein value from the total cholesterol value obtained through a standard lipid panel. As an illustration, if an individual’s total cholesterol is 200 mg/dL and their high-density lipoprotein cholesterol is 50 mg/dL, the resulting value would be 150 mg/dL.
This value serves as a significant indicator of cardiovascular risk. Its utility lies in encompassing various atherogenic lipoproteins, providing a more complete picture than low-density lipoprotein cholesterol alone. Monitoring these levels assists healthcare professionals in assessing an individual’s likelihood of developing heart disease and guides therapeutic interventions. Historically, emphasis was primarily placed on low-density lipoprotein cholesterol; however, recognizing the contribution of other cholesterol-carrying particles has led to the increased adoption of this more comprehensive metric.
Understanding the derived value contributes significantly to the formulation of personalized strategies for managing lipid profiles and mitigating potential cardiovascular complications. Subsequent sections will explore optimal ranges, factors influencing levels, and the role of this metric in conjunction with other cardiovascular risk assessments.
1. Total Cholesterol Value
The total cholesterol value constitutes a fundamental component in determining non-high-density lipoprotein cholesterol. Its accuracy and reliability directly influence the resulting assessment, which is subsequently used to gauge cardiovascular risk.
-
Direct Impact on Calculation
The total cholesterol reading is the starting point. Any inaccuracies in this measurement will propagate directly into the calculation. For example, if the total cholesterol is erroneously reported as 220 mg/dL instead of 200 mg/dL, the derived non-HDL value will be artificially inflated by 20 mg/dL, potentially leading to misinterpretation and inappropriate clinical decisions.
-
Influence on Therapeutic Targets
Clinical guidelines often use total cholesterol as a preliminary indicator for further lipid analysis. Elevated total cholesterol often triggers a more in-depth assessment, including non-HDL cholesterol, to refine risk stratification and establish appropriate therapeutic goals. A falsely low total cholesterol might delay the assessment and postpone necessary interventions.
-
Laboratory Measurement Variability
Variability in laboratory assays can affect the precision of the total cholesterol measurement. Factors such as calibration standards, reagent quality, and analyzer performance all contribute to potential fluctuations. Consistent monitoring of laboratory quality control metrics is crucial to minimize measurement errors and ensure accurate calculation of non-HDL cholesterol.
-
Interdependence with HDL Cholesterol
The calculation relies on subtracting high-density lipoprotein cholesterol from the total cholesterol. While total cholesterol is directly measured, its relationship to the HDL cholesterol component is critical. The ratio of the two components contributes to the derived assessment. Therefore, both measurements must be reliable for accurate cardiovascular risk assessment.
In conclusion, the total cholesterol reading forms an integral and inseparable part of the derived metric. Ensuring the accuracy and reliability of this component is essential for informed decision-making and effective management of cardiovascular risk.
2. HDL Cholesterol Subtraction
The process of subtracting high-density lipoprotein (HDL) cholesterol from total cholesterol is a defining step in the calculation of non-high-density lipoprotein cholesterol. Its precise execution directly impacts the clinical utility of the resulting value.
-
Quantifying Atherogenic Lipoproteins
The subtraction effectively isolates the concentration of cholesterol contained within potentially atherogenic lipoproteins. By removing HDL cholesterol, which is associated with cardioprotective effects, the remainder represents cholesterol in VLDL, IDL, and LDL particles. For example, a high total cholesterol with a correspondingly high HDL cholesterol may yield a lower, less concerning result. Conversely, a seemingly moderate total cholesterol coupled with low HDL may reveal a more elevated and concerning value.
-
Impact on Risk Stratification
The derived value directly informs risk stratification algorithms used to assess an individual’s likelihood of developing cardiovascular disease. Higher values indicate a greater concentration of atherogenic particles and, consequently, an elevated risk. Clinicians use this information to tailor preventive and therapeutic strategies, such as lifestyle modifications or pharmacological interventions, to mitigate the identified risk.
-
Influence on Treatment Decisions
The calculated level serves as a critical parameter in guiding treatment decisions, particularly regarding lipid-lowering therapies. Individuals with elevated levels despite adequate LDL cholesterol control may require additional interventions to address the residual risk associated with non-HDL cholesterol. Statins, for instance, are commonly prescribed to lower LDL, but may also have a beneficial impact on this calculated value by reducing VLDL cholesterol.
-
Precision and Accuracy Considerations
The accuracy of the subtraction is contingent upon the precision of both the total cholesterol and HDL cholesterol measurements. Any inaccuracies in either component will propagate directly into the final result, potentially leading to misinterpretations. Rigorous quality control measures in the laboratory are essential to minimize measurement errors and ensure the reliability of the calculated value.
In summary, HDL cholesterol subtraction forms the cornerstone of the calculation, effectively isolating and quantifying the cholesterol content within atherogenic lipoproteins. The resultant value plays a crucial role in risk stratification, treatment decisions, and overall cardiovascular disease management.
3. VLDL Contribution
Very-low-density lipoprotein (VLDL) significantly impacts the calculation, as VLDL particles inherently contribute to the total cholesterol pool from which high-density lipoprotein (HDL) cholesterol is subtracted. Understanding the extent of this involvement is crucial for accurate interpretation.
-
Direct Inclusion in Calculation
Since VLDL cholesterol is not directly measured in standard lipid panels, its contribution is captured within the total cholesterol value. The subtraction of HDL cholesterol leaves behind cholesterol from LDL and VLDL, thus including VLDLs cholesterol content in the resulting figure. For example, individuals with high triglyceride levels often have elevated VLDL cholesterol, which consequently increases the value, even if LDL cholesterol is within the target range. This underscores the necessity of considering VLDL when assessing cardiovascular risk using this metric.
-
Influence on Cardiovascular Risk Assessment
Elevated VLDL cholesterol is independently associated with increased cardiovascular risk. The derived value, by encompassing VLDL cholesterol, provides a more comprehensive assessment of atherogenic lipoproteins compared to LDL cholesterol alone. This is particularly relevant in individuals with metabolic syndrome or diabetes, where VLDL levels are often elevated. The derived value helps clinicians identify individuals at increased risk who might be missed by focusing solely on LDL cholesterol.
-
Implications for Therapeutic Strategies
The VLDL component guides therapeutic decision-making, especially when the calculated level remains elevated despite achieving target LDL cholesterol levels. In such cases, interventions targeting triglycerides and VLDL cholesterol, such as lifestyle modifications or fibrate medications, may be warranted. For instance, an individual with controlled LDL but persistent elevation in the calculated level might benefit from dietary changes focused on reducing carbohydrate intake to lower triglycerides and, consequently, VLDL cholesterol.
-
Relationship with Triglycerides
VLDL cholesterol levels are closely correlated with triglyceride levels, as VLDL particles are the primary carriers of triglycerides in the bloodstream. High triglyceride levels typically indicate increased VLDL cholesterol, which directly impacts the calculation. Consequently, monitoring triglyceride levels provides valuable context for interpreting the derived value. Lowering triglycerides through dietary changes or medication can effectively reduce VLDL cholesterol, thereby lowering the result and mitigating cardiovascular risk.
The assessment tools utility stems from its ability to capture the atherogenic potential of VLDL, providing a more complete picture of cardiovascular risk. By considering the VLDL contribution, clinicians can tailor interventions more effectively and address the multifaceted nature of dyslipidemia.
4. LDL Imprecision
Direct low-density lipoprotein cholesterol measurement is not always accurate, especially at elevated triglyceride levels. The Friedewald equation, often used to estimate LDL cholesterol, becomes unreliable when triglycerides exceed 400 mg/dL. This equation estimates LDL cholesterol by subtracting high-density lipoprotein cholesterol and an estimate of very-low-density lipoprotein cholesterol (triglycerides/5) from total cholesterol. If triglycerides are high, the estimated VLDL cholesterol becomes inflated, leading to an underestimation of LDL cholesterol. In such instances, the calculated value provides a more accurate reflection of atherogenic cholesterol because it isn’t subject to the same limitations as the Friedewald estimation. For example, an individual with a total cholesterol of 250 mg/dL, HDL of 40 mg/dL, and triglycerides of 500 mg/dL, the Friedewald-estimated LDL would be 150 mg/dL. However, this estimate is unreliable due to the high triglycerides. In this case, calculating the result (250 – 40 = 210 mg/dL) provides a more accurate representation of the patients atherogenic burden.
The consequence of inaccurate LDL measurements can be significant. Over-reliance on the Friedewald equation in patients with hypertriglyceridemia could lead to underestimation of cardiovascular risk and potentially inadequate treatment. In clinical practice, this could translate to a patient not receiving necessary lipid-lowering therapy due to a falsely reassuring LDL cholesterol value, when, in fact, their true atherogenic cholesterol burden, as reflected by the calculated value, warrants intervention. Furthermore, direct LDL cholesterol measurements, while more accurate than the Friedewald estimation, can still exhibit variability depending on the laboratory method used, adding another layer of complexity to interpretation. Therefore, clinicians should consider both direct and calculated measurements when evaluating a patient’s lipid profile.
In summary, the imprecision associated with LDL cholesterol measurement, particularly when estimated using the Friedewald equation or when influenced by laboratory variability, underscores the importance of the calculated value. It offers a more robust and inclusive assessment of atherogenic lipoproteins, circumventing some of the limitations inherent in LDL cholesterol measurement alone. Utilizing this value, especially in the context of hypertriglyceridemia or when LDL measurement is questionable, is a valuable strategy for more accurate cardiovascular risk assessment and targeted therapeutic intervention.
5. Atherogenic Risk Indicator
The calculated value serves as a crucial indicator of atherogenic risk. By encompassing all cholesterol fractions that contribute to plaque formation within arteries, it provides a more complete assessment of cardiovascular risk than low-density lipoprotein cholesterol alone. This is particularly relevant given the heterogeneity of lipoprotein particles and their variable atherogenic potential.
-
Comprehensive Assessment of Lipoprotein Burden
The calculated value integrates cholesterol carried by various atherogenic lipoproteins, including VLDL, IDL, and remnants. This broad assessment is significant because these particles contribute to plaque formation, particularly in individuals with elevated triglycerides or metabolic syndrome. For instance, a patient with controlled LDL cholesterol but elevated triglycerides may still have an elevated level, signaling residual risk that would be missed by focusing solely on LDL cholesterol. This comprehensive approach allows for more targeted risk management.
-
Guidance for Therapeutic Intervention
Elevated levels directly influence therapeutic decisions. Clinical guidelines often recommend targeting it as a secondary goal when LDL cholesterol targets have been achieved but cardiovascular risk remains high. This might involve lifestyle modifications, such as dietary changes and increased physical activity, or the addition of medications to lower triglycerides and VLDL cholesterol. For example, if a patient’s LDL cholesterol is at goal but the level remains elevated, a clinician might prescribe a fibrate or niacin to further reduce atherogenic lipoproteins.
-
Early Identification of Dyslipidemia Patterns
The calculation can help identify atherogenic dyslipidemia patterns that might not be apparent from standard lipid panels. Individuals with insulin resistance or type 2 diabetes often exhibit a pattern of elevated triglycerides, low HDL cholesterol, and increased small, dense LDL particles. While standard LDL cholesterol measurements might not fully capture the risk associated with this pattern, the calculated value will reflect the increased atherogenic burden. This allows for earlier intervention and more aggressive risk factor management.
-
Monitoring Treatment Response and Residual Risk
The assessment is valuable for monitoring treatment response and assessing residual cardiovascular risk. Even after achieving LDL cholesterol targets, some individuals remain at increased risk due to elevated triglycerides, low HDL cholesterol, or other factors. Monitoring the derived value helps clinicians identify those individuals who may benefit from additional therapies to address their residual risk. For instance, a patient on statin therapy who achieves target LDL cholesterol but still has an elevated value may require additional treatment to further reduce their risk.
In summary, the assessment tool serves as a valuable indicator of atherogenic risk by providing a more comprehensive assessment of atherogenic lipoproteins and guiding therapeutic decision-making. Its utility lies in its ability to capture the cumulative impact of various cholesterol fractions on cardiovascular risk, allowing for more personalized and effective risk management strategies.
6. Triglyceride Influence
Triglyceride levels exert a considerable influence on the calculation, primarily because elevated triglycerides often correlate with increased very-low-density lipoprotein (VLDL) cholesterol. This relationship affects the overall cholesterol balance and the interpretation of cardiovascular risk.
-
VLDL Cholesterol Correlation
Triglycerides are primarily carried in the blood by VLDL particles. As triglyceride levels rise, the concentration of VLDL cholesterol typically increases as well. Since VLDL cholesterol is included within the total cholesterol measurement, but not directly measured in standard lipid panels, elevated triglycerides indirectly inflate the value. For example, a patient with high triglycerides may have a seemingly normal LDL cholesterol level, but the increased VLDL cholesterol contributes to an elevated resulting value, signaling increased atherogenic risk.
-
Friedewald Equation Limitations
The Friedewald equation, often used to estimate LDL cholesterol, becomes unreliable at triglyceride levels above 400 mg/dL. This equation estimates LDL cholesterol by subtracting HDL cholesterol and an estimate of VLDL cholesterol (triglycerides/5) from total cholesterol. At high triglyceride levels, the estimated VLDL cholesterol becomes disproportionately large, leading to an underestimation of LDL cholesterol. The calculated value circumvents this limitation, providing a more accurate assessment of atherogenic cholesterol in individuals with hypertriglyceridemia.
-
Impact on Risk Stratification
Elevated triglycerides, and consequently increased VLDL cholesterol, are independently associated with increased cardiovascular risk. The result, by encompassing VLDL cholesterol, provides a more complete assessment of atherogenic lipoproteins compared to LDL cholesterol alone. This is particularly relevant in individuals with metabolic syndrome or diabetes, where VLDL levels are often elevated. The result helps clinicians identify individuals at increased risk who might be missed by focusing solely on LDL cholesterol.
-
Therapeutic Implications
The triglyceride influence guides therapeutic decision-making, especially when the calculated value remains elevated despite achieving target LDL cholesterol levels. In such cases, interventions targeting triglycerides and VLDL cholesterol, such as lifestyle modifications or fibrate medications, may be warranted. For instance, an individual with controlled LDL but persistent elevation in the calculated value might benefit from dietary changes focused on reducing carbohydrate intake to lower triglycerides and, consequently, VLDL cholesterol.
In conclusion, triglyceride levels significantly impact the derived result by influencing VLDL cholesterol concentrations and affecting the accuracy of LDL cholesterol estimations. Understanding this influence is crucial for accurate cardiovascular risk assessment and targeted therapeutic interventions.
7. Cardiovascular Assessment
The relationship between cardiovascular assessment and the derived value is fundamental to evaluating an individual’s risk of developing heart disease. This assessment involves a comprehensive evaluation of various risk factors, with the calculated value serving as a critical component in determining overall cardiovascular health.
-
Risk Stratification Refinement
The value enhances risk stratification beyond traditional lipid panels. While LDL cholesterol is a primary target for treatment, the value encompasses all atherogenic lipoproteins, providing a more complete picture of cardiovascular risk. For example, individuals with metabolic syndrome or diabetes may have controlled LDL levels but elevated triglycerides and VLDL cholesterol, resulting in a higher, more accurate indicator of risk. This refined stratification guides clinicians in tailoring interventions to address specific lipid abnormalities and mitigate cardiovascular risk more effectively.
-
Comprehensive Lipid Profile Interpretation
Cardiovascular assessment relies on interpreting the entire lipid profile, including total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The calculated value integrates these components into a single metric, simplifying the assessment process. For example, if a patient has borderline high LDL cholesterol but low HDL cholesterol, the derived value will reflect the imbalance and provide a clearer indication of the overall atherogenic burden. This integrated approach helps clinicians make informed decisions about treatment strategies and lifestyle modifications.
-
Guidance for Therapeutic Targets
The level guides the establishment of therapeutic targets for lipid-lowering interventions. Clinical guidelines often recommend targeting the calculation as a secondary goal after achieving LDL cholesterol targets, especially in individuals with high triglycerides or other risk factors. For example, if a patient’s LDL cholesterol is at goal, but the calculated value remains elevated, clinicians may consider additional therapies, such as fibrates or omega-3 fatty acids, to further reduce atherogenic lipoproteins and lower the resultant value. This targeted approach ensures that treatment is tailored to the individual’s specific lipid profile and cardiovascular risk.
-
Monitoring Treatment Efficacy
The assessment is used to monitor the effectiveness of lipid-lowering therapies and lifestyle modifications. Regular monitoring of the value helps clinicians assess whether interventions are effectively reducing atherogenic lipoproteins and mitigating cardiovascular risk. For example, if a patient’s level decreases in response to statin therapy and dietary changes, it indicates that the interventions are having a positive impact on their overall lipid profile. This ongoing monitoring allows for adjustments to treatment strategies as needed to optimize cardiovascular outcomes.
In summary, cardiovascular assessment relies heavily on the derived measurement as a comprehensive indicator of atherogenic risk. By incorporating all relevant cholesterol fractions, the value enhances risk stratification, guides therapeutic decision-making, and monitors treatment efficacy, ultimately contributing to improved cardiovascular outcomes.
8. Therapeutic Target
The derived value serves as a significant therapeutic target in the management of dyslipidemia and the reduction of cardiovascular risk. It provides a comprehensive assessment of atherogenic lipoproteins, guiding clinicians in tailoring treatment strategies to address individual patient needs.
-
Primary Treatment Goal When LDL Achieved
When low-density lipoprotein cholesterol targets have been met, the value often becomes the subsequent focus of lipid-lowering therapy. This is particularly relevant in individuals with elevated triglycerides, diabetes, or metabolic syndrome, where residual cardiovascular risk remains despite adequate LDL control. For instance, a patient achieving an LDL cholesterol of less than 70 mg/dL might still have an elevated level due to high VLDL cholesterol, necessitating further intervention with medications like fibrates or omega-3 fatty acids to lower triglycerides and, consequently, the resultant value.
-
Guiding Statin Intensification
In cases where initial statin therapy does not adequately reduce the resulting figure, statin intensification may be warranted. The decision to increase the statin dose or add a non-statin agent, such as ezetimibe, is often guided by the patient’s baseline and on-treatment levels. For example, a patient with a high baseline assessment might require a high-intensity statin to achieve a significant reduction in both LDL cholesterol and value. Regular monitoring of these parameters helps clinicians optimize treatment regimens to minimize cardiovascular risk.
-
Informing Non-Statin Therapy Selection
The level assists in selecting appropriate non-statin therapies for patients who are unable to tolerate statins or require additional lipid-lowering beyond statin monotherapy. Fibrates, niacin, and PCSK9 inhibitors are among the options that may be considered based on the patient’s specific lipid profile and cardiovascular risk factors. For instance, a patient with statin intolerance and elevated triglycerides might benefit from fibrate therapy, which primarily targets VLDL cholesterol and can effectively lower the assessment value.
-
Monitoring Treatment Response and Adherence
Regular monitoring of the calculation is crucial for assessing treatment response and adherence. A significant reduction in the value indicates that the chosen therapy is effectively lowering atherogenic lipoproteins and reducing cardiovascular risk. Conversely, a lack of response may suggest poor adherence, the need for treatment intensification, or the presence of underlying factors contributing to dyslipidemia. For example, a patient with consistently elevated levels despite prescribed medications may require further evaluation to identify and address potential barriers to treatment adherence or underlying metabolic disorders.
The value serves as a critical therapeutic target in managing dyslipidemia and reducing cardiovascular risk. By guiding treatment decisions, informing therapy selection, and monitoring treatment response, it plays a central role in personalized lipid management strategies aimed at improving cardiovascular outcomes.
Frequently Asked Questions
The following addresses common inquiries regarding the assessment tool, its interpretation, and clinical implications. Information presented is intended to enhance understanding and should not substitute professional medical advice.
Question 1: What distinguishes the non-HDL cholesterol value from LDL cholesterol?
The primary distinction lies in the scope of cholesterol fractions encompassed. Low-density lipoprotein cholesterol (LDL-C) represents cholesterol carried specifically within LDL particles. The result, conversely, reflects cholesterol contained in all atherogenic lipoproteins, including LDL, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein(a) [Lp(a)]. This provides a more comprehensive assessment of atherogenic burden.
Question 2: When is assessment of the derived metric particularly important?
Assessment is particularly valuable in individuals with elevated triglyceride levels (above 200 mg/dL), diabetes mellitus, metabolic syndrome, or a family history of premature cardiovascular disease. In these populations, standard LDL-C measurements may underestimate the true atherogenic risk, and the derived value provides a more accurate representation.
Question 3: What constitutes an optimal level of non-HDL cholesterol?
Optimal levels vary based on individual risk factors. However, general guidelines suggest the following targets: Desirable: Less than 130 mg/dL, Borderline High: 130-159 mg/dL, High: 160-189 mg/dL, Very High: 190 mg/dL and above. These targets should be individualized based on a patient’s overall cardiovascular risk profile.
Question 4: How is the metric calculated?
The calculation is straightforward: Total Cholesterol minus High-Density Lipoprotein Cholesterol (HDL-C). This simple calculation utilizes values obtained from a standard lipid panel.
Question 5: What lifestyle modifications can lower the level?
Effective lifestyle modifications include adopting a heart-healthy diet low in saturated and trans fats, engaging in regular physical activity (at least 150 minutes of moderate-intensity exercise per week), maintaining a healthy weight, and abstaining from smoking. These interventions can significantly impact lipid profiles and reduce cardiovascular risk.
Question 6: Does the derived metric replace the need to monitor LDL cholesterol?
No, the value does not replace the need for LDL-C monitoring. LDL-C remains a primary target for lipid-lowering therapy. The calculation serves as a complementary metric, providing additional insight into atherogenic risk and guiding therapeutic decisions, particularly when LDL-C targets have been achieved but residual risk remains.
In summary, the calculator offers a comprehensive measure of atherogenic cholesterol, valuable for refining risk assessment and guiding therapeutic interventions. Its utility is especially pronounced in individuals with complex lipid profiles or elevated cardiovascular risk.
The subsequent section explores the clinical implications of managing levels and integrating this metric into overall cardiovascular disease prevention strategies.
Navigating the Assessment
The following offers targeted guidance to enhance comprehension and application of the calculated parameter, designed for healthcare professionals and individuals seeking detailed insights.
Tip 1: Validate Measurements: Confirm the accuracy of total cholesterol and high-density lipoprotein cholesterol (HDL-C) values before calculation. Inaccurate input values directly compromise the validity of the assessment.
Tip 2: Consider Triglyceride Levels: Recognize the influence of triglycerides on the metric. Elevated triglycerides often correlate with increased very-low-density lipoprotein cholesterol (VLDL-C), indirectly affecting the assessment. Interpret results cautiously in individuals with hypertriglyceridemia.
Tip 3: Integrate with Risk Assessment Tools: Employ the calculated value in conjunction with established cardiovascular risk assessment tools. Its integration improves the precision of risk stratification, particularly in complex cases.
Tip 4: Individualize Therapeutic Targets: Establish individualized therapeutic targets based on the patient’s overall cardiovascular risk profile. Standard target levels may not be appropriate for all individuals. Account for factors such as age, sex, family history, and presence of comorbidities.
Tip 5: Monitor Treatment Response: Regularly monitor the levels to assess the effectiveness of lipid-lowering therapies and lifestyle modifications. Consistent monitoring allows for timely adjustments to treatment strategies.
Tip 6: Account for Non-Fasting Samples: Be mindful that the calculation may be less accurate when using non-fasting lipid panels, particularly if triglyceride levels are elevated. Fasting lipid panels provide more reliable data for calculating and interpreting the result.
Key takeaways: The assessment serves as a valuable tool for refining cardiovascular risk assessment and guiding therapeutic interventions. Accurate measurement, contextual interpretation, and individualized treatment strategies are paramount.
Moving forward, understanding the clinical context and applying these tips allows for more effective management of dyslipidemia and reduced cardiovascular risk.
Conclusion
The preceding analysis has detailed the significance of non hdl cholesterol calculator as a tool for evaluating cardiovascular risk. The assessment incorporates various atherogenic lipoproteins, circumventing limitations inherent in relying solely on low-density lipoprotein cholesterol measurements. Its application is particularly salient in individuals presenting with hypertriglyceridemia, metabolic syndrome, or diabetes mellitus, conditions where standard lipid panels may underestimate the true atherogenic burden.
Consistent with evidence-based guidelines, accurate interpretation and implementation of the derived value necessitates careful consideration of individual patient factors and integration with comprehensive cardiovascular risk assessments. Ongoing research and clinical practice will likely further refine the understanding and utilization of this metric in the prevention and management of atherosclerotic cardiovascular disease.
